We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. Moderna Inc. (NASDAQ:MRNA) was one of ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Moderna said on Monday it expects to report around $1.9  billion in sales for 2025, putting it near the upper end of its ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day. The stock ...

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...

An update from Moderna ( ($MRNA) ) is now available. In a January 5, 2026 letter to shareholders, Moderna reviewed a challenging 2025 operating ...